Comparison of underwater endoscopic mucosal resection and endoscopic submucosal dissection of rectal neuroendocrine tumors (with videos)
- PMID: 31904380
- DOI: 10.1016/j.gie.2019.12.039
Comparison of underwater endoscopic mucosal resection and endoscopic submucosal dissection of rectal neuroendocrine tumors (with videos)
Abstract
Background and aims: The first choice of treatment for rectal neuroendocrine tumors (NETs) ≤10 mm in size is endoscopic resection. However, because rectal NETs usually invade the submucosal layer, achieving R0 resection is difficult. Endoscopic submucosal dissection (ESD) has a high R0 resection rate, and underwater endoscopic mucosal resection (UEMR) was recently introduced to ensure a negative resection margin easily and safely. The aim of this study was to evaluate the efficacy and safety of UEMR versus ESD for rectal NETs ≤10 mm in size.
Methods: This retrospective observational study enrolled 115 patients with rectal NETs ≤10 mm in size who underwent ESD or UEMR between January 2015 and July 2019 at the National Cancer Center, Korea. The differences in R0 resection rate, adverse event rate, and procedure time between the ESD and UEMR groups were evaluated.
Results: Of the 115 patients, 36 underwent UEMR and 79 underwent ESD. The R0 resection rate was not different between the UEMR and ESD groups (UEMR vs ESD, 86.1% vs 86.1%, P = .996). The procedure time was significantly shorter with UEMR (UEMR vs ESD, 5.8 ± 2.9 vs 26.6 ±13.4 minutes, P < .001). Two patients (2.5%, 2/79) experienced adverse events in the ESD group and but there were no adverse events in the UEMR group; however, this difference was not statistically significant.
Conclusion: UEMR is a safe and effective technique that should be considered when removing small rectal NETs. Further studies are warranted to define its role compared with ESD.
Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Comment in
-
Underwater EMR or endoscopic submucosal dissection for rectal neuroendocrine tumors: What are the advantages?Gastrointest Endosc. 2020 Jul;92(1):230-231. doi: 10.1016/j.gie.2020.02.008. Gastrointest Endosc. 2020. PMID: 32586554 No abstract available.
-
Response.Gastrointest Endosc. 2020 Jul;92(1):231. doi: 10.1016/j.gie.2020.03.004. Gastrointest Endosc. 2020. PMID: 32586556 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous